azacitidine and bexarotene

azacitidine has been researched along with bexarotene in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Abboud, CN; Cashen, AF; Dipersio, JF; Jacoby, M; Niu, H; Pusic, I; Schroeder, MA; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P	1

Reviews

1 review(s) available for azacitidine and bexarotene

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

1 trial(s) available for azacitidine and bexarotene

Article	Year
A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. American journal of hematology, 2014, Volume: 89, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Animals; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Azacitidine; Bexarotene; Decitabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gene Expression; Gene Expression Profiling; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Mice; Middle Aged; Receptors, Retinoic Acid; Recurrence; Retinoic Acid Receptor alpha; Retinoid X Receptor alpha; Tetrahydronaphthalenes; Tumor Cells, Cultured	2014

Article

Year

A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.

American journal of hematology, 2014, Volume: 89, Issue:8

Topics: Administration, Oral; Aged; Aged, 80 and over; Animals; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Azacitidine; Bexarotene; Decitabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gene Expression; Gene Expression Profiling; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Mice; Middle Aged; Receptors, Retinoic Acid; Recurrence; Retinoic Acid Receptor alpha; Retinoid X Receptor alpha; Tetrahydronaphthalenes; Tumor Cells, Cultured

2014